When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Become Profitable?
When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Become Profitable?
We feel now is a pretty good time to analyse Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) business as it appears the company may be on the cusp of a considerable accomplishment. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. With the latest financial year loss of US$140m and a trailing-twelve-month loss of US$111m, the US$7.3b market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Intra-Cellular Therapies' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.
我们认为现在分析 Intra-Cellular Therapies, Inc.(纳斯达克股票代码:ITCI)的业务是一个非常好的时机,因为该公司似乎即将取得重大成就。Intra-Cellular Therapies, Inc.是一家生物制药公司,主要在美国以靶向中枢神经系统(CNS)的胞内信号转导机制的小分子药物的探索、临床开发和商业化为重点,解决神经精神和神经系统疾病的医疗需求。截至最新财年,该公司亏损了1.4亿美元,过去12个月的亏损为1.11亿美元,这家市值73亿美元的公司正在接近实现盈利平衡的目标,这是投资者最为关注的问题。以下是该公司业内分析师对公司的预测的高层次总结。
According to the 15 industry analysts covering Intra-Cellular Therapies, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of US$116m in 2025. Therefore, the company is expected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 60% is expected, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
根据对Intra-Cellular Therapies的15名行业分析师的调查,共识是该公司已经接近盈亏平衡点。他们预计该公司将在2024年发布最终的亏损报告,然后在2025年实现1.16亿美元的利润,因此该公司预计在一年多的时间内实现盈亏平衡点。为了达到这个盈亏平衡点,我们计算了公司必须年均增长的速度。它得出的结果是预计平均年增长率为60%,这是相当乐观的!如果企业增长速度缓慢,将比预期的时间更晚实现盈利。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240707/0-36bbcc30291c0e9459c870550a530c91-0-867d35286072bce7b6e8ae45ea852acb.png/big)
Given this is a high-level overview, we won't go into details of Intra-Cellular Therapies' upcoming projects, however, take into account that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
由于这是一个高层次的概述,我们不会详细介绍Intra-Cellular Therapies即将推出的项目。但需要考虑到,一家制药公司通常拥有波动的现金流,这取决于该企业所处的药品和产品开发阶段。这意味着公司即将迎来大量增长并不是不正常的,因为公司正在开始收获早期投资的好处。
One thing we'd like to point out is that Intra-Cellular Therapies has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
我们想指出一件事:Intra-Cellular Therapies的资产负债表上没有任何债务,这对于一个消耗现金的制药公司来说是相当不寻常的,因为这类公司通常相对于股本拥有很高的债务。该公司目前完全依靠股东提供资金,没有任何债务义务,这减少了还款方面的风险,使其成为一个风险较小的投资。
Next Steps:
下一步:
There are too many aspects of Intra-Cellular Therapies to cover in one brief article, but the key fundamentals for the company can all be found in one place – Intra-Cellular Therapies' company page on Simply Wall St. We've also compiled a list of essential factors you should further research:
Intra-Cellular Therapies的方方面面不能在一篇简短的文章中全部涵盖,但是该公司的关键基本面可以在一个地方找到——Simply Wall St的Intra-Cellular Therapies公司页面。我们还编制了一个必要性因素的列表供您进一步研究:
- Valuation: What is Intra-Cellular Therapies worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Intra-Cellular Therapies is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Intra-Cellular Therapies's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Intra-Cellular Therapies今天的价值是多少?未来的增长潜力是否已经被市场纳入价格?我们的免费研究报告中的内在价值信息图表可以帮助您直观地了解Intra-Cellular Therapies是否被市场低估。
- 管理团队:有经验的管理团队在舵手上增加了我们对该业务的信心——请查看谁在Intra-Cellular Therapies的董事会上和首席执行官的背景。
- 其他高表现的股票:是否有其他表现更好的股票并具有经过验证的历史记录?查看这里的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。